either.fi Finance system

[either.fi Finance system @etheri_fie]

Voting is live to choose the release date for $ETHFI rewards.

Joining gives you access to an extra allocation when rewards are paid.

Learn more ⤵️
https://t.co/UyiMoKQqjR

[either.fi Finance system @etheri_fie]

@ether_fi /2 Don't miss out—vote now to help decide when $ETHFI rewards go live! 🔥

Participating boosts your allocation when distribution begins.

Details here ⤵️

https://t.co/52rLbVSmhe

[Travala @travalacom]

Book from 50,000+ car rental locations with 100+ crypto options on Travala!

[Kate from Kharkiv @BohuslavskaKate]

Newly released photos of destroyed Kupyansk, a town killed by russia for daring to reclaim its freedom from occupation.

Life used to thrive here, streets were filled with laughter and daily hustle. Then came russians.

[Ben Rhodes @brhodes]

One of my first jobs in politics was a 2001 Brooklyn city council race (h/t Diana Reyna) where I wrote letters for Chinese-American residents of public housing to be translated into Mandarin. This is some next level outreach by a generational talent.

[BET88PHOFFICIAL @Bet88PH]

Play JILI Super Ace for FREE! Sign up now at BET88 to claim instantly, no deposit required!

[Jamie Dupree @jamiedupree]

There must be some experts on this app about stone / rock / building materials. Here is a photo of a support column from the early 1800's at the U.S. Capitol. Any idea what this might be? 1/

[Fermat's Library @fermatslibrary]

The last course Enrico Fermi taught before his death was introductory quantum mechanics, in the winter and spring quarters of 1954. Here is the last exam Fermi gave with his own solutions for each problem.

[POLITICO @politico]

Sen. Mark Kelly is raising money, building political favors and showing up in politically significant states. 

All signs point to a 2028 run, but what is Kelly actually saying?

Our @DashaBurns and @adamwren discuss on Playbook Podcast: https://t.co/SUoAGXFCI0

[BC.GAME @bcgame]

To Get Up to$6000 deposit bonus in BC GAME!

[Massimo @Rainmaker1973]

How animals react when their people pretend to fall

[either.fi Finance system @etheri_fie]

dsa

[Merus @MerusNV]

The interim data presented today at #AACR23 highlights clinically meaningful activity of petosemtamab monotherapy observed in previously treated #HNSCC

#CloseInOnCancer

https://t.co/WX4RoRtghn

[Merus @MerusNV]

Merus Announces Publication of an Abstract on Petosemtamab Monotherapy in Previously Treated Head and Neck Squamous Cell Carcinoma for Plenary Session Oral Presentation at #AACR23 and Provides a Program and Regulatory Update.
https://t.co/aBdu4eltD5

[Merus @MerusNV]

At #AACR23, we’ll present interim clinical data on petosemtamab in #HNSCC at an oral plenary session, plus interim clinical data in
advanced gastric/esophageal adenocarcinoma and preclinical data on MCLA-129 targeting EGFR and c-MET on solid tumor cells.
#CloseInOnCancer

[either.fi Finance system @etheri_fie]

Congrats! to the teams @CRISPRTX and @VertexPharma, and all who made this possible.

Some reflections on the early days from CRISPR discovery to creating exa-cel and bringing it into the clinic - & foundational work of @BostonChildrens Stu Orkin & team
https://t.co/FvPZTAIu07

[CRISPR Therapeutics @CRISPRTX]

We are pleased to announce that we’ve completed the submission of our Biologics License Applications (BLAs) to the U.S. FDA for our potential treatment for sickle cell disease and beta thalassemia. Learn more: https://t.co/u3dNx9DC80

[Merus @MerusNV]

Encouraging #Zeno case report in #NRG1 fusion breast cancer in #JCOPO: Metabolic and RECIST tumor response > 21 months and ongoing in a heavily pretreated patient. NRG1 fusions occur in the absence of other cancer driver mutations
@MerusNV $MRUS
https://t.co/VTCZPS7ytN

[Alison Schram @AliSchram]

In case you missed it, updated results from the eNRGy study presented at #ASCO22! Zeno ORR of 34% (27/79) across tumor types & 42% (8/19) in PDAC. Median DOR of 9.1 mo and extremely well tolerated. Zeno has the potential to become new SOC for this unmet clinical need.

[Merus @MerusNV]

Dr. @AliSchram #MSKCC presented updated data from the #Zeno phase 1/2 eNRGy trial and Early Access Program which are assessing the safety and anti-tumor activity of #Zeno in #NRG1+ cancer at #ASCO2022 #CloseInOnCancer $MRUS
https://t.co/jrJlixzg7u

[Merus @MerusNV]

Excited to attend #ASCO2022 and looking forward to sharing at ASCO [June 5, 9:45a CT] an interim clinical data update of zenocutuzumab, a HER2 x HER3 bispecific antibody, in advanced #NRG1 fusion (NRG1+) cancers.
https://t.co/djZwKkkYWT